MX2023006289A - Farmaco para aliviar el dolor neuropatico. - Google Patents
Farmaco para aliviar el dolor neuropatico.Info
- Publication number
- MX2023006289A MX2023006289A MX2023006289A MX2023006289A MX2023006289A MX 2023006289 A MX2023006289 A MX 2023006289A MX 2023006289 A MX2023006289 A MX 2023006289A MX 2023006289 A MX2023006289 A MX 2023006289A MX 2023006289 A MX2023006289 A MX 2023006289A
- Authority
- MX
- Mexico
- Prior art keywords
- neuropathic pain
- medicine
- alleviating neuropathic
- alleviating
- attenuate
- Prior art date
Links
- 208000004296 neuralgia Diseases 0.000 title abstract 2
- 208000021722 neuropathic pain Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 abstract 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020199206 | 2020-11-30 | ||
| PCT/JP2021/043375 WO2022114122A1 (ja) | 2020-11-30 | 2021-11-26 | 神経障害性疼痛を緩和させるための医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006289A true MX2023006289A (es) | 2023-07-31 |
Family
ID=81755628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006289A MX2023006289A (es) | 2020-11-30 | 2021-11-26 | Farmaco para aliviar el dolor neuropatico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240009180A1 (https=) |
| EP (1) | EP4272758A4 (https=) |
| JP (1) | JPWO2022114122A1 (https=) |
| KR (1) | KR20230096055A (https=) |
| CN (1) | CN116782901A (https=) |
| AU (1) | AU2021389409A1 (https=) |
| CA (1) | CA3198258A1 (https=) |
| IL (1) | IL302972A (https=) |
| MX (1) | MX2023006289A (https=) |
| TW (1) | TW202237111A (https=) |
| WO (1) | WO2022114122A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121159455A (zh) * | 2024-06-18 | 2025-12-19 | 武汉人福创新药物研发中心有限公司 | 氨基酯类化合物及其作为p2x7拮抗剂的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013269606B2 (en) | 2012-06-01 | 2018-05-17 | Ablynx N.V. | P2X7 receptor antagonists and agonists |
| JP6301920B2 (ja) | 2013-05-27 | 2018-03-28 | 国立大学法人 岡山大学 | 疼痛治療薬 |
| US11077100B2 (en) * | 2017-03-13 | 2021-08-03 | Raqualia Pharma Inc. | Tetrahydroquinoline derivatives as P2X7 receptor antagonists |
| EP3398941A1 (en) | 2017-05-03 | 2018-11-07 | AXXAM S.p.A. | Heterocyclic p2x7 antagonists |
| JP7311944B2 (ja) | 2018-04-16 | 2023-07-20 | 塩野義製薬株式会社 | 二環性含窒素複素環誘導体を含有する医薬組成物 |
| JP2019182806A (ja) | 2018-04-16 | 2019-10-24 | 塩野義製薬株式会社 | 二環性複素環誘導体およびそれらを含有する医薬組成物 |
-
2021
- 2021-11-26 JP JP2022565447A patent/JPWO2022114122A1/ja not_active Withdrawn
- 2021-11-26 US US18/254,270 patent/US20240009180A1/en active Pending
- 2021-11-26 EP EP21898094.4A patent/EP4272758A4/en not_active Withdrawn
- 2021-11-26 IL IL302972A patent/IL302972A/en unknown
- 2021-11-26 AU AU2021389409A patent/AU2021389409A1/en not_active Abandoned
- 2021-11-26 TW TW110144115A patent/TW202237111A/zh unknown
- 2021-11-26 KR KR1020237017766A patent/KR20230096055A/ko not_active Withdrawn
- 2021-11-26 CA CA3198258A patent/CA3198258A1/en active Pending
- 2021-11-26 CN CN202180080359.2A patent/CN116782901A/zh active Pending
- 2021-11-26 WO PCT/JP2021/043375 patent/WO2022114122A1/ja not_active Ceased
- 2021-11-26 MX MX2023006289A patent/MX2023006289A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116782901A (zh) | 2023-09-19 |
| WO2022114122A1 (ja) | 2022-06-02 |
| US20240009180A1 (en) | 2024-01-11 |
| KR20230096055A (ko) | 2023-06-29 |
| EP4272758A1 (en) | 2023-11-08 |
| EP4272758A4 (en) | 2025-01-29 |
| JPWO2022114122A1 (https=) | 2022-06-02 |
| CA3198258A1 (en) | 2022-06-02 |
| IL302972A (en) | 2023-07-01 |
| TW202237111A (zh) | 2022-10-01 |
| AU2021389409A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013155A2 (es) | Moduladores de nlrp3 | |
| MX2025007468A (es) | Composiciones y metodos para el manejo de trastornos | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| CO2024007129A2 (es) | Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
| CO2019007205A2 (es) | Usos terapéuticos de un polvo de insectos | |
| CL2020000085A1 (es) | Moduladores de nlrp3. | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| MX2021009285A (es) | Anticuerpos novedosos de unión a la proteína de antígenos de diferenciación 40 (cd40). | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| DOP2024000060A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| BR112021018456A2 (pt) | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| BR112017012381A2 (pt) | imunoterapia para doença angiogênica | |
| BR112016027435A2 (pt) | formulação inovadora de meloxicam | |
| UY40610A (es) | Inhibidores de kif18a y usos de los mismos | |
| CL2018003502A1 (es) | Métodos para tratar la osificación heterotópica. | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| CL2019000661A1 (es) | Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica. | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| MX2023000763A (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. | |
| MX2023006289A (es) | Farmaco para aliviar el dolor neuropatico. |